Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $NKTR
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/14/2025 | $6.00 | Perform → Outperform | Oppenheimer |
1/8/2025 | $4.00 | Buy | B. Riley Securities |
12/10/2024 | $6.50 | Buy | H.C. Wainwright |
11/4/2024 | $7.00 | Overweight | Piper Sandler |
9/30/2024 | $4.00 | Buy | BTIG Research |
6/28/2024 | $2.00 | Buy | Rodman & Renshaw |
11/20/2023 | Underweight | JP Morgan | |
11/9/2023 | Market Perform → Outperform | TD Cowen |
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
SAN FRANCISCO, March 20, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 27, 2025 at 2:00 p.m. Eastern Time / 11:00 a.m. Pacific Time – webcast link hereThe fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-pres
Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
SAN FRANCISCO, March 12, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash and investments in marketable securities on December 31, 2024 were $269.1 million as compared to $329.4 million at December 31, 2023. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the fourth quarter of 2026. "The significant progress we made last year in advancing our immunology pipeline positions us for two value-creating data milestones in 20
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, March 5, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2024 on Wednesday, March 12, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar w
Nektar Therapeutics upgraded by Oppenheimer with a new price target
Oppenheimer upgraded Nektar Therapeutics from Perform to Outperform and set a new price target of $6.00
B. Riley Securities initiated coverage on Nektar Therapeutics with a new price target
B. Riley Securities initiated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $4.00
H.C. Wainwright initiated coverage on Nektar Therapeutics with a new price target
H.C. Wainwright initiated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $6.50
Chief R&D Officer Zalevsky Jonathan sold $10,403 worth of shares (10,300 units at $1.01), decreasing direct ownership by 3% to 316,604 units (SEC Form 4)
4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
Chief Legal Officer Wilson Mark Andrew sold $11,150 worth of shares (11,040 units at $1.01), decreasing direct ownership by 3% to 324,292 units (SEC Form 4)
4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
President & CEO Robin Howard W sold $24,012 worth of shares (23,774 units at $1.01), decreasing direct ownership by 2% to 1,086,901 units (SEC Form 4)
4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
SEC Form S-8 filed by Nektar Therapeutics
S-8 - NEKTAR THERAPEUTICS (0000906709) (Filer)
SEC Form 10-K filed by Nektar Therapeutics
10-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
Nektar Therapeutics filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh
BigHat Biosciences Appoints Rob Chess, Serial Entrepreneur, to its Board of Directors
BigHat Biosciences, a biotechnology company designing safer, more effective next-generation antibody therapies for patients using machine learning and synthetic biology, today announced that Rob Chess has been elected to BigHat's board of directors. Rob brings valuable experience in corporate biotech leadership and business strategy, from having led innovative and diverse teams from inception to successful exits to serving on the boards of multiple private and public life sciences companies. "We look forward to leveraging Rob's deep expertise in drug discovery and development to accelerate our work creating better antibody therapies for patients," said Mark DePristo, PhD., BigHat's CEO and
Nektar Therapeutics Strengthens Board of Directors with Appointment of Diana M. Brainard, M.D.
SAN FRANCISCO, Nov. 15, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced it has appointed Diana M. Brainard, M.D., as an independent director to its Board of Directors. Dr. Brainard brings over two decades of experience working in the healthcare sector and academia to Nektar. She currently serves as Chief Executive Officer (CEO) of AlloVir, Inc., a leading late clinical stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. "We are very ple
Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
SAN FRANCISCO, March 12, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash and investments in marketable securities on December 31, 2024 were $269.1 million as compared to $329.4 million at December 31, 2023. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the fourth quarter of 2026. "The significant progress we made last year in advancing our immunology pipeline positions us for two value-creating data milestones in 20
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, March 5, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2024 on Wednesday, March 12, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar w
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th
SAN FRANCISCO, Feb. 24, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that it will host a virtual investor and analyst event with Type 1 Diabetes (T1D) Experts on Monday, February 24, 2025 at 3:00 p.m. EST / 12:00 p.m. PST. Nektar's Chief Research & Development Officer, Jonathan Zalevsky, Ph.D., will be hosting the webcasted event. He will be joined by leading Diabetes experts, including: Dr. Kevin Herold, TrialNet Chair and C.N.H. Long Professor of Immunobiology and Medicine at Yale University at Yale School of Medicine;Dr. Megan Levings, Professor, D
SEC Form SC 13G filed by Nektar Therapeutics
SC 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)
Amendment: SEC Form SC 13G/A filed by Nektar Therapeutics
SC 13G/A - NEKTAR THERAPEUTICS (0000906709) (Subject)
SEC Form SC 13G filed by Nektar Therapeutics
SC 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)